CVM (36) GNTA (50) MGX (24) ALGS (22) ⌘ Pro Terminal →

Evaxion A/S (EVAX) — RQD Stock Rating Cockpit

$2.93 -4.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.90

Evaxion A/S (EVAX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $27.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EVAX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EVAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Evaxion A/S (NASDAQ: EVAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $2.93 (-4.87% 1D, market cap $27.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EVAX ranks #329 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EVAX compare to CVM and GNTA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EVAX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CVM (Cel-Sci Corporation) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $26.4M) and GNTA (Genenta Science S.p.A.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $29.9M). Among the 5-stock peer group, EVAX leads on earnings multiple (N/A) while CVM leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EVAX?

▼

For Evaxion A/S (EVAX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #329 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.90 (-1.07%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EVAX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY EVAX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($778.0K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$3.00+11% Next Q

Q2 (-2Q)

Grade C-$3.33-7.5% Next Q

Q3 (-1Q)

Grade C-$3.08-4.9% Next Q

Current

Grade D$2.93-5.6% Hist 90D α

Trajectory: C (56) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EVAX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EVAX currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.18) and Max Pain ($3.08) forces dealer call-delta covering toward $7.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EVAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EVAX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

47.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $3$2.93H: $7

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on EVAX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

14/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like EVAX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EVAX)

✓Walkthrough of EVAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EVAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.89%📐 HORIZONTAL RANGE

2026-11-02O $3.11H $3.11L $2.93C $2.93VOL 41.3K

RES: $4.59SUP: $2.64SMA50: $3.18SMA200: $3.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EVAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EVAX Butterfly Map → + Track EVAX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EVAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EVAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EVAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EVAX)

Health Care Rank #329 of 1016 ⚔️ CVM vs EVAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EVAX vs. CVM, GNTA, MGX, ALGS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Evaxion A/S (EVAX) ranks #329 by composite RQD confidence (48/100, grade D) and #812 by equity capitalization ($27.8M). Within this direct 5-issuer industry benchmark cohort, EVAX leads on earnings valuation at N/A trailing P/E, while CVM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with EVAX at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EVAX ACTIVE Evaxion A/S	D	48/100	—	—	—	-4.87%	$27.8M	Benchmark Subject
CVM Cel-Sci Corporation	D-	36/100	—	—	-35.0%	-8.00%	$26.4M	/cvm-vs-evax →
GNTA Genenta Science S.p.A.	D	50/100	—	—	—	-0.27%	$29.9M	/gnta-vs-evax →
MGX Metagenomi Therapeutics Inc.	E	24/100	—	—	-35.0%	-6.01%	$31.4M	/mgx-vs-evax →
ALGS Aligos Therapeutics Inc.	E	22/100	—	—	-35.0%	-4.57%	$31.4M	/algs-vs-evax →

2. EVAX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Evaxion A/S (EVAX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $27.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. EVAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EVAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EVAX compare to CVM and GNTA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EVAX?

Where is EVAX trading relative to its 50-day, 200-day, and 52-week technical levels?

EVAX last traded at $2.93 (-4.87% on volume of 46,205 shares), positioning the stock -7.86% below its 50-day simple moving average ($3.18) and -16.05% below its 200-day simple moving average ($3.49). Across its 52-week range of $2.72 to $6.92, EVAX sits at the 5.0% percentile with a 14-day RSI of 47.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.56 to $3.30).

EVAX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell EVAX stock right now?

Evaxion A/S (EVAX) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is EVAX's 12-month price target and RQD AI Jury consensus?

EVAX's 12-month base price target is $2.8 (range $2.18 to $7.27), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: EVAX RQD Cockpit EVAX 12M Forecast EVAX Earnings & Move EVAX Dividends & DRIP EVAX Insiders & 13F EVAX Whale Options EVAX Profit Sankey EVAX News & Why

ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EVAX — Evaxion A/S: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EVAX scores 48 out of 100, grade D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). Per the Roarable RQD rating, the cash-generation pillar is weak because the source data reports no return on invested capital and no free-cash-flow yield.
Whale 13F Flow: 5 / 20 (institutional accumulation and options positioning). This is the lowest pillar, indicating weak institutional support in the rating's framework.
Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). The rating scores insider and congressional flow as weak.
Macro Regime Fit: 9 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock is rated as moving in line with the broader market, without a defensive or high-volatility profile.
Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, with a Piotroski score of 6 out of 9 and a Debt/Equity ratio of 0.5 per the rating.

For a prospective investor, the rating's composition suggests the balance sheet is the most supportive element, while cash generation, institutional flow, and insider conviction are the weakest. The upside case rests on balance-sheet resilience and any future improvement in cash generation; the downside case rests on the absence of reported profitability and the lack of visible institutional or insider accumulation. The rating is a quantitative framework output and is not a recommendation.

Recent Catalysts & News Wire Analysis

Per the recent news wire, six items all relate to EVAX and carry a YELLOW light with a MARKET WIRE impact label:

Yahoo! Finance Canada and Yahoo Finance UK items cover general market action, institutional positioning, and fundamental catalysts without specific event detail.
Moomoo covers a forecast and analyst-ratings page without specific rating figures in the summary.
Seeking Alpha reports a slideshow discussing EVX-01 Phase II clinical and immune data in advanced melanoma.
Two Stock Titan items report that a Danish company won the Prix Galien for the first time, with Evaxion's AI platform named best digital health solution.

Risk watch items: the source contains no earnings, revenue, or guidance data, and the Butterfly graph reports no supply-chain links or proprietary signals. The news wire offers no quantified financial catalyst. Per the market data, the price fell 0.96% and volume was 41,318 at the time of the snapshot.

Open Questions

What are the reported revenue, operating income, net income, and free cash flow figures for recent periods, given that the financials section contains no data?
What is the company's cash balance and total debt, and what is its runway relative to its cash burn?
What is the status and timing of the EVX-01 Phase II program referenced in the news wire, and what do the clinical data indicate?
Who are the institutional holders, insiders, and congressional traders, and what is their recent activity?
Why are trailing and forward P/E and EPS unavailable, and does the company currently report positive earnings?

EVAX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Evaxion A/S (EVAX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EVAX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 9h ago

Evaxion A/S (EVAX) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 12h ago

Evaxion A/S (EVAX) Stock Forecast & Analyst Ratings

Moomoo report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 15h ago

Evaxion A/S (EVAX) stock price, news, quote and history

Yahoo Finance UK report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 18h ago

Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma - Slideshow

Seeking Alpha report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 21h ago

A Danish company wins the Prix Galien for the first time. Evaxion's AI platform was named best digital health solution.

Stock Titan report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A Danish company wins this international health award for the first time: Evaxion (EVAX).

Stock Titan report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

After two years with KEYTRUDA, patients received Evaxion (EVAX)'s cancer vaccine alone in year 3.

Stock Titan report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Evaxion A/S Stock Price Today | EVAX Live Chart & News

Traders Union report covering Evaxion A/S (EVAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EVAX Bull vs. Bear Conversation Board — What's Your Call at $2.93?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EVAX 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.33 (+8.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EVAX (D • RQD 48/100) a Buy at $3.08?

Welcome to the EVAX (Evaxion A/S) Roar Pit. Current RQD Composite is 48/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.53 (-17.9%)

Spot @ $3.08

Pump the brakes on EVAX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EVAX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Evaxion A/S expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.88 (+26.0%)

Spot @ $3.08

EVAX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EVAX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $3.08 (52-wk range $2.72 - $6.92), any beat on forward guidance forces shorts and underweight funds to chase.